Sign In
Buy ARDX
$6.18
-0.190 (-2.98%)
At Close: Jun 23, 2026
Ardelyx (ARDX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
07:31pm, Thursday, 30'th Oct 2025
While the top- and bottom-line numbers for Ardelyx (ARDX) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compa
Ardelyx (ARDX) Reports Break-Even Earnings for Q3
06:41pm, Thursday, 30'th Oct 2025
Ardelyx (ARDX) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to break-even earnings per share a year ago.
Ardelyx Reports Third Quarter 2025 Financial Results and Provides Corporate Update
04:01pm, Thursday, 30'th Oct 2025
Q3 2025 product revenue of $105.5 million reflects 15% year-over-year growth IBSRELA ® Q3 revenue of $78.2 million reflects 92% year-over-year growth; IBSRELA guidance raised, 2025 revenue expected t
IBSRELA patients reported treatment satisfaction in real-world survey Post-hoc analysis of T3MPO-1 and T3MPO-2 studies demonstrates effectiveness of IBSRELA in reducing abdominal bloating for patients
Ardelyx Announces Four Abstracts Accepted for Poster Presentations at the American Society of Nephrology's Kidney Week
08:00am, Tuesday, 21'st Oct 2025
WALTHAM, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class med
Ardelyx to Report Third Quarter 2025 Financial Results on October 30, 2025
08:35am, Monday, 13'th Oct 2025
WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class med
Ardelyx Appoints Experienced Finance Executive, Sue Hohenleitner, as Chief Financial Officer
08:30am, Monday, 13'th Oct 2025
WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class med
Ardelyx, Inc. (ARDX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
10:11am, Monday, 08'th Sep 2025
Ardelyx, Inc. (NASDAQ:ARDX ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 7:00 AM EDT Company Participants Michael Raab - President, CEO & Director Eric Foster - Chief Com
Ardelyx, Inc. (ARDX) Presents At Citi's Biopharma Back To School Conference Transcript
04:42pm, Wednesday, 03'rd Sep 2025
Ardelyx, Inc. (NASDAQ:ARDX ) Citi's Biopharma Back to School Conference September 3, 2025 1:00 PM EDT Company Participants Michael Raab - President, CEO & Director Eric Foster - Chief Commercial Offic
Ardelyx to Participate in Upcoming Investor Conferences
08:00am, Monday, 25'th Aug 2025
WALTHAM, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class med
Ardelyx: Improved Outlook For Ibsrela And Xphozah
06:17am, Friday, 15'th Aug 2025
The share price of Ardelyx has finally broken the year-long downtrend after a strong second quarter earnings report. Ibsrela returned to stronger topline growth in Q2 and the company raised the full-y
Ardelyx Q2 Revenue Jumps 33%
12:41pm, Tuesday, 05'th Aug 2025
Ardelyx Q2 Revenue Jumps 33%
Ardelyx, Inc. (ARDX) Q2 2025 Earnings Call Transcript
08:11pm, Monday, 04'th Aug 2025
Ardelyx, Inc. (NASDAQ:ARDX ) Q2 2025 Earnings Conference Call August 4, 2025 4:30 PM ET Company Participants Caitlin Lowie - Vice President of Corporate Communications & Investor Relations Eric Duane
Ardelyx (ARDX) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
07:32pm, Monday, 04'th Aug 2025
The headline numbers for Ardelyx (ARDX) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates
Ardelyx (ARDX) Reports Q2 Loss, Tops Revenue Estimates
06:30pm, Monday, 04'th Aug 2025
Ardelyx (ARDX) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.07 per share a year ago.
